She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

US pharma giant Pfizer has announced positive results from the Phase III TALAPRO-2 study of Talzenna (talazoparib), an oral ...

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower ...

Pfizer (PFE) announced results from the Phase 3 TALAPRO-2 study of TALZENNA, an oral poly ADP-ribose polymerase inhibitor, in combination with ...